HCPCS Codes Similar to G9143

HCPCS Codes Similar to “G9143” Code.
Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)

G9199 Venous thromboembolism (vte) prophylaxis not administered the day of or the day after hospital admission for documented reasons (eg, patient is ambulatory, patient expired during inpatient stay, patient already on warfarin or another anticoagulant, other medical reason(s) or eg, patient left against medical advice, other patient reason(s)) Code added date: 20140101 Code effective date: 20150101 TXT \| PDF \| XML \| JSON	U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 Code added date: 20210101 Code effective date: 20230512 TXT \| PDF \| XML \| JSON
G0659 Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes Code added date: 20170101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON	G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion Code added date: 20160101 Code effective date: 20160101 TXT \| PDF \| XML \| JSON
G0455 Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen Code added date: 20130101 Code effective date: 20130101 TXT \| PDF \| XML \| JSON	G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed Code added date: 20160101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed Code added date: 20160101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON	G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed Code added date: 20160101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed Code added date: 20160101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON	M1409 Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis Code added date: 20250101 Code effective date: 20250101 TXT \| PDF \| XML \| JSON
M1410 Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis Code added date: 20250101 Code effective date: 20250101 TXT \| PDF \| XML \| JSON	S3800 Genetic testing for amyotrophic lateral sclerosis (als) Code added date: 20070701 Code effective date: 20070701 TXT \| PDF \| XML \| JSON
S3830 Complete mlh1 and msh2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing Code added date: 20020101 Code effective date: 20120401 TXT \| PDF \| XML \| JSON	S3831 Single-mutation analysis (in individual with a known mlh1 and msh2 mutation in the family) for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing Code added date: 20020101 Code effective date: 20120401 TXT \| PDF \| XML \| JSON